Eagle Pharmaceuticals’ Pemetrexed NDA Accepted for Filing by the FDA

09:01 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or “the Company”) today announced that the 505(b)(2) New Drug Application (NDA) for its novel Pemetrexed Injection, 25 mg/mL has been accepted for filing by the U.S. Fo...

Other Sources for this Article

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson, 212-452-2793


More From BioPortfolio on "Eagle Pharmaceuticals’ Pemetrexed NDA Accepted for Filing by the FDA"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...